



Sandrine FAIVRE, MD, PhD (France) - sandrine.faivre@aphp.fr

Biography:

Professor of Medical Oncology at the University Paris VII (Denis Diderot), Clinical and Translational Research, Head and Neck & Digestive Oncology at Bichat-Beaujon University Hospitals, Hôpitaux Universitaires Paris Nord Val de Seine, Paris.

She graduated and was board certified in medical oncology in 1998. Working on cell signalling associated with heterotrimeric G-proteins and their role in cellular invasion, she obtained her Ph.D. in cellular and molecular biology in 2002. After a post doctoral fellowship at the Cancer Therapy and Research Center & Institute for Drug Development at the University of Texas in San Antonio, she spent 6 years at Gustave-Roussy Institute in Villejuif (1998-2004) working on clinical and translational research in phase I-II clinical studies on early drug development where she was also coordinator of head and neck oncology.

She has been investigator of a more than 100 phase I/II studies and published the first-in-man phase I trial of sunitinib malate that led to pivotal phase III and fast track registration of sunitinib in kidney cancer. She also participated to first-in-man phase I trials with mTOR inhibitors CCI-779 (temsirolimus) and RAD001 (everolimus) and to the investigation of molecular biomarkers of sensitivity/resistance to those agents.

When joining Paris' Assistance Publique-Hôpitaux de Paris in 2005, she has focused on trials in head and neck tumors and gastrointestinal oncology including hepatobiliary malignancies, gastrointestinal neuroendocrine tumors and phase I/II trials with new molecules including molecular pharmacology and translational research.

She is a member of the American Association for Cancer Research, American Society of Clinical Oncology, European Society of Medical Oncology, International Liver Cancer Association. She has published more than 170 peer-reviewed papers.